二甲双胍抗肿瘤作用的分子机制研究进展

doi:10.12092/j.issn.1009-2501.2019.03.019

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (3): 350-354.doi: 10.12092/j.issn.1009-2501.2019.03.019

二甲双胍抗肿瘤作用的分子机制研究进展

丁秋花，史道华

福建医科大学附属福建省妇幼保健院药剂科，福州 350001，福建

收稿日期:2018-12-27 修回日期:2019-02-16 出版日期:2019-03-26 发布日期:2019-04-01
通讯作者: 史道华，男，博士，教授，主任药师，研究方向：临床药学与药理学。 Tel：0591- 88312079 E-mail: shidh@fjmu.edu.cn
作者简介:丁秋花，女，药师，在职硕士研究生，研究方向：妇科肿瘤药物治疗学。 Tel：13515004421 E-mail：qiuhua830808@163.com
基金资助:
福建省自然科学基金资助项目（2017J01234）

Advances on the molecular mechanism of metformin's antitumor effect

DING Qiuhua, SHI Daohua

Department of Pharmacy , Fujian Provincial Maternity and Children's Hospital,Affiliated Hospital of Fujian Medical University, Fuzhou 350001, Fujian,China

Received:2018-12-27 Revised:2019-02-16 Online:2019-03-26 Published:2019-04-01

摘要/Abstract

摘要：

二甲双胍作为经典的2型糖尿病治疗药物，其作用安全有效，在临床上被广泛应用于降血糖。近来研究发现，使用人群中恶性肿瘤的发病率和死亡率较低，二甲双胍可能为潜在的抗肿瘤药，其机制尚不明确，相关通路的研究有利于揭示其抗肿瘤的作用机理，对于寻找肿瘤治疗靶点和开发其作为新的抗肿瘤药物具有重要意义。本文从AMPK依赖和非依赖的角度，对二甲双胍抑制肿瘤作用的分子机制进行综述。

关键词: 二甲双胍, 肿瘤, AMPK, 分子机制

Abstract:

Metformin is a classical drug with safety and efficacy for type 2 diabetes therapies, which are widely used in hypoglycemia. According to recent study, the morbidity and mortality of malignant tumors are lower in patients. Although the mechanism is unclear, metformin might become a potential antitumor drug. Research on the related pathways serves to reveal its mechanism, which is great significance for developing novel antitumor targets and drugs. This article reviews the molecular mechanisms of metformin on inhibition of tumors in AMPK dependent and non-dependent way.

Key words: metformin, tumor, AMPK, molecular mechanisms

中图分类号:

R966

丁秋花，史道华. 二甲双胍抗肿瘤作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 350-354.

DING Qiuhua, SHI Daohua. Advances on the molecular mechanism of metformin's antitumor effect[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 350-354.

参考文献

［1］Shi Y, Hu FB. The global implications of diabetes and cancer［J］. Lancet, 2014, 383(9933): 1947-1948.
［2］Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients［J］. BMJ, 2005, 330(7503): 1304-1305.
［3］Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis［J］. PLoS One, 2012, 7(3): e33411.
［4］Vancura A, Bu P, Bhagwat M, et al. Metformin as an Anticancer Agent［J］. Trends Pharmacol Sci, 2018, 39(10): 867-878.
［5］Umezawa S, Higurashi T, Nakajima A. AMPK: Therapeutic Target for Diabetes and Cancer Prevention［J］. Curr Pharm Des, 2017, 23(25): 3629-3644.
［6］Kurumbail RG, Calabrese MF. Structure and Regulation of AMPK［J］. EXS, 2016, 107: 3-22.
［7］Li W, Saud SM, Young MR, et al. Targeting AMPK for cancer prevention and treatment［J］. Oncotarget, 2015, 6(10): 7365-7378.
［8］Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells［J］. Cancer Res, 2006, 66(21): 10269-10273.
［9］Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression［J］. Oncogene, 2008, 27(55): 6908-6919.
［10］Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade［J］. Curr Biol, 2003, 13(22): 2004-2008.
［11］Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signaling in cancer［J］. Biochim Biophys Acta, 2013, 1835(2): 194-210.
［12］Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice［J］. Biochem J, 2008, 412(2): 211-221.
［13］Li NS, Zou JR, Lin H, et al. LKB1/AMPK inhibits TGF-beta1 production and the TGF-beta signaling pathway in breast cancer cells［J］. Tumour Biol, 2016, 37(6): 8249-8258.
［14］Green AS, Chapuis N, Maciel TT, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation［J］. Blood, 2010, 116(20): 4262-4273.
［15］Hardie DG. The LKB1-AMPK pathway-friend or foe in cancer?［J］. Cancer Cell, 2013, 23(2): 131-132.
［16］Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth［J］. Br J Clin Pharmacol, 2019, 85(1): 37-46.
［17］Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells［J］. Cancer Res, 2007, 67(22): 10804-10812.
［18］Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways［J］. J Exp Clin Cancer Res, 2018, 37(1): 63.
［19］Wandee J, Prawan A, Senggunprai L, et al. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway［J］. Life Sci, 2018, 207: 172-183.
［20］Zakikhani M, Blouin MJ, Piura E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells［J］. Breast Cancer Res Treat, 2010, 123(1): 271-279.
［21］Kamada R, Toguchi Y, Nomura T, et al. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications［J］. Biopolymers, 2016, 106(4): 598-612.
［22］Sun Y, Tao C, Huang X, et al. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway［J］. Onco Targets Ther, 2016, 9: 2845-2853.
［23］Li P, Zhao M, Parris AB, et al. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells［J］. Biochem Biophys Res Commun, 2015, 464(4): 1267-1274.
［24］Gwak H, Kim Y, An H, et al. Metformin induces degradation of cyclin D1 via AMPK/GSK3beta axis in ovarian cancer［J］. Mol Carcinog, 2017, 56(2): 349-358.
［25］Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer［J］. Nature, 2018, 559(7715): 637-641.
［26］Cha JH, Yang WH, Xia W, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1［J］. Mol Cell, 2018, 71(4): 606-620.
［27］Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner［J］. Cell Metab, 2010, 11(5): 390-401.
［28］Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells［J］. Cell Cycle, 2009, 8(1): 88-96.
［29］Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer［J］. J Endocrinol Invest, 2016, 39(12): 1365-1376.
［30］Simpson A, Petnga W, Macaulay VM, et al. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies［J］. Target Oncol, 2017, 12(5): 571-597.
［31］Sarfstein R, Friedman Y, Attias-Geva Z, et al. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners［J］. PLoS One, 2013, 8(4): e61537.
［32］Li L, Wang Y, Peng T, et al. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway［J］. Oncotarget, 2016, 7(23): 34442-34452.
［33］Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap［J］. Front Mol Biosci, 2018, 5: 86.
［34］Zhao Y, Sun H, Feng M, et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling［J］. Gynecol Endocrinol, 2018, 34(5): 428-432.
［35］Zheng Z, Zhu W, Yang B, et al. The co-treatment of metformin with flavone synergistically induces apoptosis through inhibition of PI3K/AKT pathway in breast cancer cells［J］. Oncol Lett, 2018, 15(4): 5952-5958.
［36］Shi P, Liu W, Tala, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation［J］. Cell Discov, 2017, 3: 17010.
［37］Chung YC, Chang CM, Wei WC, et al. Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells［J］. Sci Rep, 2018, 8(1): 3930.
［38］Garrido MP, Vera C, Vega M, et al. Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells［J］. Ther Adv Med Oncol, 2018, 10: 1-16.

[1]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[2]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[3]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[4]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[7]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[8]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[9]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[10]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[11]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[12]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[13]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[14]	洪子强, 苟文曦, 崔百强, 白向豆, 金大成, 苟云久. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 93-100.
[15]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.

二甲双胍抗肿瘤作用的分子机制研究进展

Advances on the molecular mechanism of metformin's antitumor effect

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价